• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Expected Phenotypes

Expected Phenotypes Expected phenotypes refer to the expected results of susceptibility tests without testing. For a species to be included in the “expected resistant phenotype”, 90% or more should be considered resistant (e.g. Klebsiella pneumoniae vs. ampicillin). For a species to be included in…

Get to know more

EUCAST abandons the term "intrinsic resistance" in favor of "expected resistant phenotype"

For many years EUCAST and other committees have struggled with the term “intrinsic resistance”. There is no agreed definition and since breakpoints are always “exposure dependent” it is hard to agree on a definition which will survive changes in dosing, modes of administration and a sudden…

Get to know more

Important Additional Information

Important Additional Information Expected phenotypes, expert rules, and detection of resistance mechanisms are important complements to susceptibility testing and should be consulted before releasing results. Expected phenotypes help with validation of identification and susceptibility tests. Expert…

Get to know more

Bacteria

Bacteria Most of EUCAST’s work is dedicated to defining breakpoints for bacteria that cause infections in humans. How to Use This Section: This page gives you access to information and services related to pathogenic bacteria. Important: All resources here are complementary. Please review them…

Get to know more

When there are no breakpoints!

The first and very important question is, when are there no breakpoints in the EUCAST breakpoint tables? Look for guidance on the interpretation of test results in breakpoint tables , expert rules and in EUCAST advice on expected phenotypes . In breakpoint tables guidance can be in the form of…

Get to know more

Resistance Detection

Resistance Detection Successful treatment of infectious diseases relies on knowledge and understanding of when antimicrobial resistance is an expected phenotype of the organism, and when resistance to antimicrobial agents may develop. The following documents provide up-to-date advice on how to…

Get to know more

Sitemap

Sitemap EUCAST - Home About EUCAST Organisation Steering Committee General Committee EUCAST Statutes National AST Committees (NAC) Network Laboratories Development Laboratories (EDL) Subcommittees Antimycobacterial Susceptibility Testing (AMST) Antifungal Susceptibility Testing (AFST) Veterinary…

Get to know more

Methodology and Instructions

Methodology and Instructions Here you find information on the EUCAST disk diffusion methodology and on MIC testing: Testing Instructions, Quality Control (QC) and Warnings. In addition, Warnings are issued by EUCAST for commercially available products, which are not performing to the expected…

Get to know more

Clinical Breakpoint Tables

Clinical Breakpoint Tables Breakpoints are part of a system for categorizing microorganisms as: Susceptible (S) Susceptible, increased exposure (I) Resistant (R) To antimicrobial agents approved for use in the treatment of infectious diseases. Information of the structure of the tables and how they…

Get to know more

EUCAST - Home

The European Committee on Antimicrobial Susceptibility Testing - EUCAST EUCAST is a scientific committee formed in 1997 and is jointly organized by ESCMID , ECDC and European national breakpoint committees. EUCAST develops antimicrobial susceptibility testing methodology, interpretative criteria and…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here